Sarah Mancone1, Thomas Lycan2, Tamjeed Ahmed2, Umit Topaloglu3, Andrew Dothard4, William J Petty2, Roy E Strowd5. 1. Department of Neurology, Wake Forest Baptist Medical Center, Winston-Salem, USA. 2. Department of Hematology and Oncology, Wake Forest Baptist Medical Center, Winston-Salem, USA. 3. Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, USA. 4. Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, USA. 5. Department of Neurology and Hematology and Oncology, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 271571, USA. rstrowd@wakehealth.edu.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are a promising class of anticancer drugs associated with immune-related adverse events (IRAEs). In registration studies of selected cancer populations, neurologic IRAEs were rare. Post-marketing experience describing their prevalence in clinical practice continues to be reported. METHODS: A retrospective cohort of patients treated at our institution with ICIs from 2005 to 2017 was identified. Patients with new neurologic ICD codes documented during or after ICI treatment were enrolled. Comprehensive medical record review identified patients with neurologic IRAEs causally linked to ICIs. This study focused on CTCAE grade 2-4 IRAEs. RESULTS: 526 patients were screened; 55 candidate patients were identified; 5 cases met criteria for neurologic IRAEs, an incidence of 0.95% (n = 5/526). IRAEs identified were transverse myelopathy, demyelinating sensorimotor polyneuropathy, oculomotor nerve palsy, sensory neuropathy, and posterior reversible encephalopathy syndrome. ICIs were held in three patients, rechallenged in one, and dose-reduced in one. Corticosteroids were given in three patients, and response varied from complete symptom resolution to minimal response and ultimately death. Other treatments were based on IRAE presentation, including gabapentin, antihypertensives, and IV immunoglobulin. Patients with combination therapy appeared to suffer more severe IRAEs producing more substantial long-term morbidity and mortality. CONCLUSION: In this clinical practice study, the incidence of neurologic IRAEs from ICIs was 0.95%. Although rare, neurologic IRAEs can be highly variable and severe, and patients with combination immunotherapy appeared to suffer more severe IRAEs. Neurologists play an important role in the early identification and management of IRAEs to reduce long-term morbidity and mortality.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are a promising class of anticancer drugs associated with immune-related adverse events (IRAEs). In registration studies of selected cancer populations, neurologic IRAEs were rare. Post-marketing experience describing their prevalence in clinical practice continues to be reported. METHODS: A retrospective cohort of patients treated at our institution with ICIs from 2005 to 2017 was identified. Patients with new neurologic ICD codes documented during or after ICI treatment were enrolled. Comprehensive medical record review identified patients with neurologic IRAEs causally linked to ICIs. This study focused on CTCAE grade 2-4 IRAEs. RESULTS: 526 patients were screened; 55 candidate patients were identified; 5 cases met criteria for neurologic IRAEs, an incidence of 0.95% (n = 5/526). IRAEs identified were transverse myelopathy, demyelinating sensorimotor polyneuropathy, oculomotor nerve palsy, sensory neuropathy, and posterior reversible encephalopathy syndrome. ICIs were held in three patients, rechallenged in one, and dose-reduced in one. Corticosteroids were given in three patients, and response varied from complete symptom resolution to minimal response and ultimately death. Other treatments were based on IRAE presentation, including gabapentin, antihypertensives, and IV immunoglobulin. Patients with combination therapy appeared to suffer more severe IRAEs producing more substantial long-term morbidity and mortality. CONCLUSION: In this clinical practice study, the incidence of neurologic IRAEs from ICIs was 0.95%. Although rare, neurologic IRAEs can be highly variable and severe, and patients with combination immunotherapy appeared to suffer more severe IRAEs. Neurologists play an important role in the early identification and management of IRAEs to reduce long-term morbidity and mortality.
Authors: Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori Journal: Lancet Oncol Date: 2015-03-31 Impact factor: 41.316
Authors: S Cuzzubbo; F Javeri; M Tissier; A Roumi; C Barlog; J Doridam; C Lebbe; C Belin; R Ursu; A F Carpentier Journal: Eur J Cancer Date: 2017-01-05 Impact factor: 9.162
Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245
Authors: James Larkin; Bartosz Chmielowski; Christopher D Lao; F Stephen Hodi; William Sharfman; Jeffrey Weber; Karijn P M Suijkerbuijk; Sergio Azevedo; Hewei Li; Daniel Reshef; Alexandre Avila; David A Reardon Journal: Oncologist Date: 2017-05-11
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Rebecca Karp Leaf; Christopher Ferreri; Deepa Rangachari; James Mier; Wesley Witteles; George Ansstas; Theodora Anagnostou; Leyre Zubiri; Zofia Piotrowska; Thein H Oo; David Iberri; Mark Yarchoan; April K S Salama; Douglas B Johnson; Andrew D Leavitt; Osama E Rahma; Kerry L Reynolds; David E Leaf Journal: Am J Hematol Date: 2019-03-13 Impact factor: 13.265
Authors: Virginie Lemiale; Anne-Pascale Meert; François Vincent; Michael Darmon; Philippe R Bauer; Andry Van de Louw; Elie Azoulay Journal: Ann Intensive Care Date: 2019-02-01 Impact factor: 6.925
Authors: Elia Sechi; Svetomir N Markovic; Andrew McKeon; Divyanshu Dubey; Teerin Liewluck; Vanda A Lennon; A Sebastian Lopez-Chiriboga; Christopher J Klein; Michelle Mauermann; Sean J Pittock; Eoin P Flanagan; Anastasia Zekeridou Journal: Neurology Date: 2020-08-13 Impact factor: 9.910